Table 3.
Age (years) | Tested drugs | Chemotherapy drugs | Clinical response | Observation time (m) | |
---|---|---|---|---|---|
Carcinosarcoma, stage IV | 68 | Paclitaxel (10 nM), carboplatin (1 μM), gemcitabine (100 nM), doxorubicin (100 nM) | None | dead | 18 days |
112-24 HGSC-1, stage IIIC | 48 | Paclitaxel (10 nM), carboplatin (2 μM), gemcitabine (100 nM), doxorubicin (1 μM) | Paclitaxel (175 mg/m2), carboplatin (AUC = 5), adding Avastin and 7.5 mg/kg5 since the third course, will be continued for 22 course | NED | 9 m |
112-25 HGSC-2, stage IIIC | 34 | Paclitaxel (15 nM), carboplatin (20 μM), gemcitabine (800 nM), doxorubicin (8 μM) | Paclitaxel (135 mg/m2), carboplatin (AUC = 5) | NED | 9 m |
NED: no evidence of disease, m: month, AUC: area under curve.